TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total fixation duration in the lower third of the face
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic follow-up rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Transaminases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total amount of analgesics used in the perioperative period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: A. actinomycetemcomians levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of IBS-D and IBS-M with SI and CDG hypomorphic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asprosin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of chronic pain after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children with moderate and serious chronic malnutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Beta-cell health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maintenance of Best Corrected Distance Visual Acuity (BCDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induced manifest refractive astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ObsQoR-10-Chinese after 60 mins
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change of ObsQoR-10-Malay after 60 mins
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Deployability of the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability of the device once inserted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radio-opacity of the device following insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinolysis status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Lipoprotein Lipase (LPL) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in LPL activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Triglycerides (TG) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Suicide composite
Endpoint domain: Adverse events/effects
Primary endpoint: Timing of surgery in the postnatal period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in satisfaction of asthma care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Unplanned reoperation or hardware failure
Endpoint domain: Adverse events/effects
Primary endpoint: neck disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Classification sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Microvascular blood flow response to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microvascular blood flow response to local heat (42 degrees Celsius)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Microvascular blood flow response to local heat (39 degrees Celsius)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: rate of inappropriate behavioural intentions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median number of hospital readmissions - Maternal
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median number of encounters for urgent or emergent care - Maternal
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of women that attend recommended postpartum visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median number of hospital readmissions - Infant
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Median number of encounters for urgent or emergent care - Infant
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of infants receiving a visit with an ambulatory care provider
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Binary reading of focal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Theta band activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of treatment with RNA-NP vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic Syndrome Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's State Anxiety Scale (CSA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SULmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adolescent body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in the NIHSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Measurement of gas exchange during 6 Minute Walk Test (6 MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of gas exchange during the Timed Up and Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of gas exchange during Graded exercise testing (GXT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of gas exchange during 10 Meter Walk Test (10MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contact coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effectiveness coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic performance of 68Ga-PSMA-dual contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of CRS
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of ICANS
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Cytopenias
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of MCG in diagnosing myocardial ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge score after completing the educational module
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients who create a research profile
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of 67Cu-SAR-bisPSMA in terms of Prostate specific Antigen (PSA) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of 67Cu-SAR-bisPSMA in terms of radiographic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of 67Cu-SAR-bisPSMA Treatment-Emergent Adverse Events [Safety and Tolerability]
Endpoint domain: Adverse events/effects
Primary endpoint: Post ligation ulcer presence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post ligation ulcer number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Post ligation ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Length of successful induction of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: hypoxaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Subjectively experienced symptoms of peripheral neuropathy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in RAND-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of Life Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in motivation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in overall functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in physical function as assessed by the SPPB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: integral time speed by cardiac transthoracic ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increased venous return gradient in percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of the placenta-derived mesenchymal stem cell product
Endpoint domain: Adverse events/effects
Primary endpoint: Change in faecal microbiome composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in gut microbial metabolite composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mortality of Pulmonary Embolism
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants who discontinued study intervention due to AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with sustained change from baseline of hematocrit to <45% without concomitant phlebotomy at Week 36
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cervical neck pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate (RT)
Endpoint domain: Mortality/survival
Primary endpoint: Identification of treatment-resistant disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with COVID-19 Symptoms Onset
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of cohort with tacrolimus concentration within therapeutic range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detachment of the umbilical cord stump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of dry or wet umbilical cord stump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild complications related to umbilical cord stump
Endpoint domain: Adverse events/effects
Primary endpoint: Selumetinib AUC0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events graded by CTCAE Ver 5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Quantitative Polymerase Chain Reaction (qPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 6-item Acceptability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ru_SATED sleep health composite
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: State-Trait Anxiety Inventory State Sub-scale (STAI-S) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microhardness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PCL-5 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in 123I-MIBG reuptake - early Heart to Mediastinal ratio (H/M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in 123I-MIBG reuptake - late Heart to Mediastinal ratio (H/M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in 123I-MIBG - Washout ratio (WR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coping Skills with Infertility Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of VTP-850 prime-boost regimens
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of GBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complications of GBS
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Safety Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Adverse Event of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Work performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with neutrophil implantation ≤ 42 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnosis of critical COVID-19 pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of Falls per month
Endpoint domain: Adverse events/effects
Primary endpoint: peri-implant soft tissue volumetric change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathology Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients diagnosed with portal hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Fistula functional success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anxiety status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of moderate and severe exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ASIA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety and tolerability of HT-4253
Endpoint domain: Adverse events/effects
Primary endpoint: response to pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in overall cognitive recovery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Responder Rate (RR) at 48 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from Baseline in proptosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle strength from baseline to 2 weeks of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle strength from baseline to 6 weeks of intervention or when the participants is discharged from the hospital
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of significant SCD-related clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants reporting systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting Adverse Event of Special Interests (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants reporting Specific Birth Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: depressive symptom
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: In-hospital Patient Mortality at 90 days from hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change in central corneal pachymetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central pain modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced AEs of Special Interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of methylation testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of methylation testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Arm Motor Assessment Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temporal parameters of Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tonic Skin Conductance Level (SCL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with stroke education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Stroke etiology recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroke risk factor recognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of Change in Area of Geographic Atrophy at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average fever duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sleep Architecture
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean difference and limits of agreement between measured and predicted BSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first negative blood culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ultrasound-Guided Attenuation Parameter (UGAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trail Making Test (TMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of ADEL-Y01
Endpoint domain: Adverse events/effects
Primary endpoint: PrEP initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Experiencing laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Dose-limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, Adolescent version (BDD-YBOCS-A)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduce wait-time adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: improve patient-centred outcomes
Endpoint domain: Life impact
Primary endpoint: reduce wait-time health care utilization
Endpoint domain: Resource use
Primary endpoint: Web module engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall acceptability of intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in the externalization of phosphatidylserine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in the adhesion to the endothelium by eryptotic erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alpha and beta diversity size of the intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of phoria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of AC/A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of fusion vergence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until first severe relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of abstinent days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Electrophysiological Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients increasing target doses of RAASi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of mycological cure at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of mycological cure at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of mycological cure at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of mycological cure at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality in 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Number of Days Cannabis Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Drinks Consumed on Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood vessel elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nitric oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Simplified Oral Hygiene Index (OHI-S) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes